| Name | Title | Contact Details |
|---|
Right from the beginning, which is now more than fifty years ago, Bruker has been driven by a single idea: to provide the best technological solution for each analytical task` Today, worldwide, more than 6,500 employees in over 90 locations on all continents are focusing their efforts on this permanent challenge` Bruker systems cover a broad spectrum of applications in all fields of research and development and are used in all industrial production processes for the purpose of ensuring quality and process reliability` Bruker continues to build upon its extensive range of products and solutions, expand its broad base of installed systems and maintain a strong reputation amongst its customers` As one of the world's leading analytical instrumentation companies, Bruker remains focused on developing state-of-the-art technologies and innovative solutions for today’s ever complex analytical questions` Bruker - Innovation with Integrity`
PAR Management is a Newton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Small publicly-traded Pharmaceutical company founded in 1998 located in New Haven, CT. Discovery and Clinical Development capabilities, specializing in anti-infectives. Several agents are in clinical trials for treating chronic hepatitis C infection..
CuraPharm Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.